DV
Dividend Vision

ARQT — Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (ARQT)

Total return is 20.1% over the past 6.5 years, 144.6 points behind SPY at 164.7%. Its deepest 1-year drawdown was 37.5%.

Arcutis Biotherapeutics is a biopharmaceutical company developing and commercializing treatments for dermatological diseases, with its lead product being ZORYVE, a topical roflumilast cream for plaque psoriasis and atopic dermatitis, along with formulations for seborrheic dermatitis and scalp conditions, and a checkpoint agonist candidate in development. The company does not currently have a known distribution rate. This security appeals to investors seeking exposure to clinical-stage and early commercial biopharmaceutical companies rather than income-focused investors.

ARQT key facts

Asset type
Stock
Asset class
Equity
Inception date
01/31/2020
Distribution frequency
None
Last close
$26.19
Market cap
$3,291,872,512
Average volume
1109500.0
Beta
1.526
Payout ratio
0.0
P/E ratio
119.0455
Forward P/E
58.8235
EPS
$0.22